Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Fri, 09.02.2024
Netfonds AG
Favorable trends to materialize in 2024
Netfonds should strongly benefit from several favorable macroeconomic and
structural trends in 2024:
Strong dollar and equity capital markets close to all-time highs. With c. €
23.2bn AuC in FY23e (eNuW), Netfonds topline is obviously correlated to the
overall capital markets development. The recen [ … ]
Thu, 08.02.2024
Singulus Technologies AG
Positive outlook after a challenging 2023
Topic: Singulus looks back at a difficult FY23 due to project postponements
and cyclical weakness. Nevertheless, there is sun behind the clouds and
FY24e looks more promising.
During the first 9M of FY23, the Solar segment showed weakness in order
intake due to postponements of larger projects. Howeve [ … ]
Wed, 07.02.2024
SFC Energy AG
First Berlin Equity Research hat ein Research Update zu SFC Energy AG
(ISIN: DE0007568578) veröffentlicht. Analyst Dr. Karsten von Blumenthal
bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 34,00.
Zusammenfassung:
SFC Energy hat vorläufige Rekordzahlen vorgelegt, die die Guidance für 2023
und unsere P [ … ]
Tue, 06.02.2024
Sernova Corp
First Berlin Equity Research has published a research update on Sernova
Corp. (ISIN: CA81732W1041). Analyst Christian Orquera reiterated his BUY
rating and maintained his CAD 3.80 price target.
Abstract:
Sernova has published FY 22/23 financial statements and provided a business
update. The figures were roughly as expected. The company reported [ … ]
Tue, 06.02.2024
Ikonisys SA
Creating a leading player in cancer diagnostics
Only weeks after Ikonisys entered a strategic partnership with Biocare
Medical, the company made the next strategic step in business development
by announcing the takeover of Hospitex, an Italian-based cytology company
specialising in oncological diagnostics. According to the company, Hospite [ … ]
Tue, 06.02.2024
Rubean AG
Promising start into 2024
Topic: Yesterday, Rubean announced to have reached more than € 340k of
sales only in January. This represents the highest monthly turnover in the
company´s history.
Rubean has realized more than one-third of previous year´s sales in only
one month. According to management, the sales-jump is the resul [ … ]
Tue, 06.02.2024
S Immo AG
Delisting indications getting stronger; chg. PT
On Friday, S IMMO announced that the company will part ways with board
member Herwig Teufelsdorfer with immediate effect. At the same time the
supervisory board decided to appoint Tomáš Salajka to the board, who is
also member of the Board of Directors of CPI Property Group (CPI), S [ … ]
Tue, 06.02.2024
Cantourage Group SE
Cannabis legalization around the corner
Topic: With the approval of the 'Cannabis Act', which is now expected to
take place at the beginning of April, Germany is seen to take a big leap
forward in regards to legalizing cannabis. This should translate into a
significant tailwind for players such as Cantourage.
As per consistent and reliable Ge [ … ]
Mon, 05.02.2024
Havila Kystruten AS
Back on course after the perfect storm
Havila Kystruten AS is a cruise line operator from Norway. Founded in 2017,
it is the only company besides the incumbent Hurtigruten Group AS mandated
by the Norwegian government to serve the 130 year old post ship service
from Bergen to Kirkenes. Next to the port-to-port service for locals, their
four ves [ … ]
Mon, 05.02.2024
creditshelf AG
GAME OVER; Suspension of recommendation
Topic: creditshelf announced that it no longer considers the key
assumptions for the company's positive going concern forecast to be
fulfilled. As a result, the company will shortly apply for protective
shield proceedings in order to secure the future of the company. In detail:
Obotritia to not meet con [ … ]
